Mandadi Tilak 4

What Happened

• Mandadi Tilak, Executive Vice President and Chief Experience & Technology Officer at CVS Health (CVS), received equity awards on 2026-03-31: 22,277 shares (awarded as restricted stock units) at $71.82 each ($1,599,934) and a derivative award of 143,712 units at $71.82 each ($10,321,396). Together the grants total approximately $11.92 million.
• Separately, 3,634 shares were surrendered on 2026-04-01 to satisfy withholding tax obligations related to vesting/settlement, at $72.49 per share for proceeds of $263,429. These were tax-withholding dispositions, not an open-market sale.

Key Details

• Transaction dates and prices:
  • 2026-03-31: Award (A) — 22,277 RSUs @ $71.82 ($1,599,934)
  • 2026-03-31: Award (A, derivative) — 143,712 units @ $71.82 ($10,321,396)
  • 2026-04-01: Tax withholding (F) — 3,634 shares surrendered @ $72.49 ($263,429)
• Shares owned after transaction: Not specified in the filing.
• Footnotes from the filing:
  • F1: Awards consist of restricted stock units under the 2017 Incentive Compensation Plan; restrictions lapse in three equal installments beginning 3/31/2027.
  • F2: Surrender of shares to pay withholding taxes upon vesting/settlement.
  • F3: One award is an option that becomes exercisable in three equal annual installments beginning 3/31/2027.
• Filing: Report filed 2026-04-02 for transactions on 2026-03-31/04-01 — appears to be a standard Form 4 filing (timely).

Context

• These transactions are grants and routine tax withholding rather than open-market purchases or opportunistic sales. Grants (RSUs/options) are compensation and typically vest over time; they do not by themselves indicate immediate bullish or bearish trading by the insider.
• The derivative/option award vests/exercises in installments starting 3/31/2027 (per F3). The surrendered shares were used solely for tax withholding (cashless portion), not an open-market sale.